Retinal Vein Occlusion Treatment Market Snapshot (2023 to 2033)
The global retinal vein occlusion treatment market is expected to be valued at US$ 2.3 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 5.9% to reach US$ 4.7 billion during forecast 2023 to 2033. Retinal vein occlusion is one of the most prevalent retinal vascular illnesses in older individuals, primarily affecting people over the age of 65. Age is a major potential risk for retinal vein occlusion. As the geriatric population rises, it is expected that the incidence of retinal vein occlusion will emerge as well.
Players in the retinal vein occlusion treatment market are expanding their capacity for producing corticosteroid drugs, which can aid in combating the inflammatory elements that cause edema. Medical practitioners, on the other side, are increasingly becoming proficient in focal laser therapy. This treatment applies lasers to places of swelling, allowing edema to reduce. Many retinal vein occlusion market stakeholders are investing more in pan-retinal photocoagulation therapy advancement and research. In instances of BRVO with neovascularization or macular edema, anti-vascular endothelial growth factor (anti-VEGF) medicines including Lucentis, Avastin, and Eylea are often used.
Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry growth. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.
Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry expansion. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.
Due to various effective healthcare facilities, an increment in the pervasiveness of eye disorders, sophisticated technology, and a boost in the ageing population, North America held a significant portion of the global retinal vein occlusion market in 2022. From 2023 to 2033, the Asia Pacific retinal vein occlusion market is predicted to grow at a 6.5% CAGR. The increasing prevalence of eye conditions in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising healthcare spending, are predicted to propel market expansion in Asia Pacific from 2023 to 2033.
The retinal vein occlusion industry in the Middle East and Africa is expected to grow due to the presence of a sophisticated medical system. Due to limited access to medical infrastructure and the sluggish advancement of the healthcare industry, the MEA market is expected to grow gradually. Nations such as Kuwait and Qatar, on the other hand, are focusing more on the medical industry and burgeoning healthcare facilities, which will strengthen the region's industry. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.
Data Points
Key Statistics
Expected Market Value (2023)
US$ 2.3 billion
Anticipated Forecast Value (2033)
US$ 4.7 billion
Projected Growth Rate (2023 to 2033)
5.9% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Retinal Vein Occlusion Treatment Demand Analysis vs. Forecast 2023 to 2033
The decline in industry growth was mainly due to the COVID-19 pandemic, which has resulted in strict containment approaches such as social distancing, remote employment, and the closure of industries and other economic operations, deriving in organizational hardships. The entire distribution chain has been impacted, which has had a negative impact on the retinal vein occlusion treatment market in the past.
However, now, that the industries are getting back to their normal functioning, theglobal demand for retinal vein occlusion treatment is projected to increase at a CAGR of 5.9% during the forecast period between 2023 and 2033, reaching a total of US$ 4.7 billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5%.
Which are Some Prominent Drivers of the Retinal Vein Occlusion Treatment Market?
The rising prevalence of Atherosclerosis and diabetes drives market expansion
The increased incidence of atherosclerosis and diabetes is predicted to drive market expansion. Because atherosclerosis is primarily asymptomatic, determining the prevalence rate is hard. Atherosclerosis is widely regarded as the leading cause of cardiovascular disease. As a result, the increasing incidence of cardiovascular diseases is attributed to the retinal vein occlusion treatment industry growth.
Based on the International Diabetes Federation (IDF), approximately 537 million adults suffered from diabetes in 2021, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. In addition, approximately 610,000 deaths occur from heart disease in the United States annually. That equates to one out of every four deaths.
Coronary heart disease is the main cause of mortality in the Western world, claiming the lives of over 370,000 people each year as per the report published in the National Library of Medicine. As a result, expanding the pervasiveness of secondary conditions may boost RVO incidence and industry growth.
Availability of Multiple Medical Therapies to fuel Market Growth
Presently, there is no therapeutic option to reverse retinal vein occlusions. There are, nevertheless, numerous medical therapies obtainable to control RVO complications. Anti-VEGF injections, corticosteroid drugs, focal laser therapy, and pan-retinal photocoagulation therapy are a few of the therapy methods. Anti-VEGF injection therapy is regarded as the first curative therapy for patient populations with BRVO or CRVO who have macular edema.
Anti-VEGF therapy has resulted in significant advances in macular edema patients. For those who suffer from macular edema, corticosteroids, such as dexamethasone implant (OZURDEX) are termed second-line therapy. Therefore, the prevalence of various therapies is predicted to drive market growth.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Projected to be Faced by the Market?
High Costs to Hinder Market Growth
The demand is anticipated to be hindered by the present unmet medical needs in the retinal vein occlusion industry for care that restores vision while remaining inexpensive.
There is no doubt that the emergence of biosimilars into the Retinal vein occlusion market will reduce expansion in the forthcoming years. During the projected timeframe, high treatment-related expenses and linked side effects of these treatments are anticipated to stymie demand.
Region-Wise Insights
What Makes North America the Largest Market for Retinal Vein Occlusion Treatment?
Extensive Development of Ophthalmology Infrastructure of the Pharmaceutical Industry to drive growth
North America would retain a huge proportion throughout the forecast timeframe. The USFDA's authorization of advanced anti-VEGF medicines in the US, the pharma industry's massive ophthalmology infrastructure, and recurring medical studies for retinal ailments all contribute to the industry's growth.
Moreover, according to the report published in Vitreous Retina Macula Consultants of New York, New York ophthalmologists and retinal ocular specialists release more research on the therapeutic interventions for branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in the leading peer-reviewed publications than any other personal or scholarly group in the USA. Also, they created numerous existing theories in retinal disease and several of the best therapeutic approaches recognized worldwide. As a result, this factor is expected to propel the market.
Why is Europe Considered a Lucrative Region for the Retinal Vein Occlusion Treatment Market?
Regulatory Drug Approvals drive Regional Market Growth
Europe is expected to have the second-largest sales volume during the forecast years owing to the high prevalence of regulatory drug approvals. The Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom approved marketing approval for Ximluci, a ranibizumab biosimilar created in collaboration between STADA Arzneimittel and Xbrane Biopharma, in January 2023. Since the approval of Teva Pharmaceuticals' Ongavia in May 2022, this is the 2nd ranibizumab biosimilar for the UK industry. Ranibizumab is a vascular endothelial growth variable obstacle used to cure retinal diseases such as retinal vein occlusion.
According to a 2018 Pubmed report, the random-effects gathered incidence of RVO in Europeans over the age of 55 was 0.7%. The overall population of affected people in the EU is expected to increase by nearly 20%, from 900,000 in 2018 to 1.1 million in 2050. The rise of a huge aged population, along with high healthcare investment, are the other attributes driving the retinal vein occlusion market expansion in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
Which Type Leads the Market for Retinal Vein Occlusion Treatment?
Branch Retinal Vein Occlusion segment held the highest market share globally
In 2022, the branch retinal vein occlusion segment held the largest global retinal vein occlusion therapeutics revenue growth. As a result of the growing incidence of elevated blood pressure, cardiovascular disease, and glaucoma, this segment is predicted to dominate the market. This segment is anticipated to expand at a CAGR of 6% over the forecast timeframe.
By End User, Which Segment is Projected to Lead the Market?
Hospitals are Estimated to Hold the Largest Share
In 2022, the hospital segment led the market, accounting for 46% of total revenue. Hospitals are usually regarded as primary healthcare systems, and the patient population's priority for hospitals for the assessment and treatment of chronic disorders is also stirring up segment growth.
Market Competition
Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc, Chugai Pharmaceuticals, Novartis AG. Some of the latest developments by the manufacturers are below
Novartis AG stated highly supportive of the initial interpretable Phase III outcomes of a clinical study examining the efficacy and security of Beovu in December 2020. Beovu by Novartis put Regeneron's anti-VEGF Eylea, one of the renowned treatments for diabetic macular edema, in direct competition.
Roche is presently conducting Phase III trials to determine the effectiveness and security of Faricimab in patient populations with macular edema secondary to BRVO and CRVO, with the drug anticipated to be approved by 2023 according to the findings.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 2.3 billion
Market Value in 2033
US$ 4.7 billion
Growth Rate
CAGR of 5.9% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug Class
Type
Diagnosis
End User
Region
Regions Covered
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Key Countries Profiled
United States
Canada
Brazil
Mexico
Mexico
Germany
United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
AbbVie
F. Hoffmann- La Roche AG
Regeneron Pharmaceuticals Inc.
Taiwan Liposome Company
Aerie Pharmaceuticals Inc.
Graybug Vision
Outlook Therapeutics
Kodiak Sciences Inc.
Chugai Pharmaceutical Co. Ltd.
Novartis AG
Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey
By Drug Class:
Ranibizumab
Dexamethasone
Aflibercept
Bevacizumab
By Type:
Central Retinal Vein Occlusion
Branch Retinal Vein Occlusion
By Diagnosis:
Optical Coherence Tomography
Fundoscopic Examination
Fluorescein Angiography
By End User:
Hospitals
Research and Academics
Specialty Clinics
By Region:
North America
Europe
East Asia
South Asia
Oceania
Latin America
Middle East and Africa (MEA)
Frequently Asked Questions
What is the Market Value in 2023?
The market value for 2023 is US$ 2.3 billion.
What is the Market Growth Outlook?
Through 2033, market sales are likely to rise at a 5.9% CAGR.
What was the Historical CAGR for the Market?
The market rose at a 5% CAGR from 2018 to 2022.
What could Limit the Retinal Vein Occlusion Treatment Sales?
Growing preference for biosimilars could hinder market growth.
Which type of Segment Leads the Market?
Branch retinal vein occlusion is likely to be the key type segment through 2033.
Table of Content
1. Executive Summary | Retinal Vein Occlusion Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Ranibizumab
5.3.2. Dexamethasone
5.3.3. Aflibercept
5.3.4. Bevacizumab
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
6.3.1. Central Retinal Vein Occlusion
6.3.2. Branch Retinal Vein Occlusion
6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis , 2023 to 2033
7.3.1. Optical Coherence Tomography
7.3.2. Fundoscopic Examination
7.3.3. Fluorescein Angiography
7.4. Y-o-Y Growth Trend Analysis By Diagnosis , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Diagnosis , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
8.3.1. Hospitals
8.3.2. Research and Academics
8.3.3. Specialty Clinics
8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The United States
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Type
10.2.4. By Diagnosis
10.2.5. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Type
10.3.4. By Diagnosis
10.3.5. By End User
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Type
11.2.4. By Diagnosis
11.2.5. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Type
11.3.4. By Diagnosis
11.3.5. By End User
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Class
12.2.3. By Type
12.2.4. By Diagnosis
12.2.5. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Type
12.3.4. By Diagnosis
12.3.5. By End User
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Class
13.2.3. By Type
13.2.4. By Diagnosis
13.2.5. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Type
13.3.4. By Diagnosis
13.3.5. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Class
14.2.3. By Type
14.2.4. By Diagnosis
14.2.5. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Type
14.3.4. By Diagnosis
14.3.5. By End User
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Class
15.2.3. By Type
15.2.4. By Diagnosis
15.2.5. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Type
15.3.4. By Diagnosis
15.3.5. By End User
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Type
16.2.4. By Diagnosis
16.2.5. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Type
16.3.4. By Diagnosis
16.3.5. By End User
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Class
17.1.2.2. By Type
17.1.2.3. By Diagnosis
17.1.2.4. By End User
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Class
17.2.2.2. By Type
17.2.2.3. By Diagnosis
17.2.2.4. By End User
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Class
17.3.2.2. By Type
17.3.2.3. By Diagnosis
17.3.2.4. By End User
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Class
17.4.2.2. By Type
17.4.2.3. By Diagnosis
17.4.2.4. By End User
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Class
17.5.2.2. By Type
17.5.2.3. By Diagnosis
17.5.2.4. By End User
17.6. UK
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Class
17.6.2.2. By Type
17.6.2.3. By Diagnosis
17.6.2.4. By End User
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Class
17.7.2.2. By Type
17.7.2.3. By Diagnosis
17.7.2.4. By End User
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Class
17.8.2.2. By Type
17.8.2.3. By Diagnosis
17.8.2.4. By End User
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Class
17.9.2.2. By Type
17.9.2.3. By Diagnosis
17.9.2.4. By End User
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Class
17.10.2.2. By Type
17.10.2.3. By Diagnosis
17.10.2.4. By End User
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Class
17.11.2.2. By Type
17.11.2.3. By Diagnosis
17.11.2.4. By End User
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Class
17.12.2.2. By Type
17.12.2.3. By Diagnosis
17.12.2.4. By End User
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Class
17.13.2.2. By Type
17.13.2.3. By Diagnosis
17.13.2.4. By End User
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Class
17.14.2.2. By Type
17.14.2.3. By Diagnosis
17.14.2.4. By End User
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Class
17.15.2.2. By Type
17.15.2.3. By Diagnosis
17.15.2.4. By End User
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Class
17.16.2.2. By Type
17.16.2.3. By Diagnosis
17.16.2.4. By End User
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Class
17.17.2.2. By Type
17.17.2.3. By Diagnosis
17.17.2.4. By End User
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Class
17.18.2.2. By Type
17.18.2.3. By Diagnosis
17.18.2.4. By End User
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Class
17.19.2.2. By Type
17.19.2.3. By Diagnosis
17.19.2.4. By End User
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Class
17.20.2.2. By Type
17.20.2.3. By Diagnosis
17.20.2.4. By End User
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Class
17.21.2.2. By Type
17.21.2.3. By Diagnosis
17.21.2.4. By End User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Type
18.3.4. By Diagnosis
18.3.5. By End User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. AbbVie
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. F. Hoffmann- La Roche AG
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Regeneron Pharmaceuticals
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Taiwan Liposome Company
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Aerie Pharmaceuticals
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Graybug Vision
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Outlook Therapeutics
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Kodiak Sciences Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Chugai Pharmaceuticals Co. Ltd.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Novartis AG
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033
Table 5: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 9: North America Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033
Table 10: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 13: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 14: Latin America Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033
Table 15: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 18: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 19: Europe Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033
Table 20: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: South Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 24: South Asia Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033
Table 25: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 27: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 28: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 29: East Asia Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033
Table 30: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 32: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 33: Oceania Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 34: Oceania Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033
Table 35: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 37: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 38: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 39: MEA Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033
Table 40: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Type, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Diagnosis , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 12: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 15: Global Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033
Figure 18: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 21: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 22: Global Market Attractiveness by Type, 2023 to 2033
Figure 23: Global Market Attractiveness by Diagnosis , 2023 to 2033
Figure 24: Global Market Attractiveness by End User, 2023 to 2033
Figure 25: Global Market Attractiveness by Region, 2023 to 2033
Figure 26: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 27: North America Market Value (US$ Million) by Type, 2023 to 2033
Figure 28: North America Market Value (US$ Million) by Diagnosis , 2023 to 2033
Figure 29: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 37: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 40: North America Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033
Figure 43: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 44: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 46: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 47: North America Market Attractiveness by Type, 2023 to 2033
Figure 48: North America Market Attractiveness by Diagnosis , 2023 to 2033
Figure 49: North America Market Attractiveness by End User, 2023 to 2033
Figure 50: North America Market Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 52: Latin America Market Value (US$ Million) by Type, 2023 to 2033
Figure 53: Latin America Market Value (US$ Million) by Diagnosis , 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 62: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 65: Latin America Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033
Figure 68: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 71: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 72: Latin America Market Attractiveness by Type, 2023 to 2033
Figure 73: Latin America Market Attractiveness by Diagnosis , 2023 to 2033
Figure 74: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 76: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 77: Europe Market Value (US$ Million) by Type, 2023 to 2033
Figure 78: Europe Market Value (US$ Million) by Diagnosis , 2023 to 2033
Figure 79: Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 87: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 88: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 90: Europe Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033
Figure 93: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 94: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 95: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 96: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 97: Europe Market Attractiveness by Type, 2023 to 2033
Figure 98: Europe Market Attractiveness by Diagnosis , 2023 to 2033
Figure 99: Europe Market Attractiveness by End User, 2023 to 2033
Figure 100: Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: South Asia Market Value (US$ Million) by Type, 2023 to 2033
Figure 103: South Asia Market Value (US$ Million) by Diagnosis , 2023 to 2033
Figure 104: South Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 110: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 112: South Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 113: South Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 115: South Asia Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033
Figure 116: South Asia Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033
Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033
Figure 118: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 119: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 120: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 121: South Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 122: South Asia Market Attractiveness by Type, 2023 to 2033
Figure 123: South Asia Market Attractiveness by Diagnosis , 2023 to 2033
Figure 124: South Asia Market Attractiveness by End User, 2023 to 2033
Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 126: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 127: East Asia Market Value (US$ Million) by Type, 2023 to 2033
Figure 128: East Asia Market Value (US$ Million) by Diagnosis , 2023 to 2033
Figure 129: East Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 137: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 138: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 140: East Asia Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033
Figure 141: East Asia Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033
Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033
Figure 143: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 144: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 145: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 146: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 147: East Asia Market Attractiveness by Type, 2023 to 2033
Figure 148: East Asia Market Attractiveness by Diagnosis , 2023 to 2033
Figure 149: East Asia Market Attractiveness by End User, 2023 to 2033
Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 151: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 152: Oceania Market Value (US$ Million) by Type, 2023 to 2033
Figure 153: Oceania Market Value (US$ Million) by Diagnosis , 2023 to 2033
Figure 154: Oceania Market Value (US$ Million) by End User, 2023 to 2033
Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 159: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 160: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 162: Oceania Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 163: Oceania Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 165: Oceania Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033
Figure 166: Oceania Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033
Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033
Figure 168: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 169: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 170: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 171: Oceania Market Attractiveness by Drug Class, 2023 to 2033
Figure 172: Oceania Market Attractiveness by Type, 2023 to 2033
Figure 173: Oceania Market Attractiveness by Diagnosis , 2023 to 2033
Figure 174: Oceania Market Attractiveness by End User, 2023 to 2033
Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 176: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 177: MEA Market Value (US$ Million) by Type, 2023 to 2033
Figure 178: MEA Market Value (US$ Million) by Diagnosis , 2023 to 2033
Figure 179: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 184: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 187: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 188: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 189: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 190: MEA Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033
Figure 191: MEA Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033
Figure 192: MEA Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033
Figure 193: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 194: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 195: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 196: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 197: MEA Market Attractiveness by Type, 2023 to 2033
Figure 198: MEA Market Attractiveness by Diagnosis , 2023 to 2033
Figure 199: MEA Market Attractiveness by End User, 2023 to 2033
Figure 200: MEA Market Attractiveness by Country, 2023 to 2033
